There is increasing evidence implicating the involvement of the immune pathways in the long-term and sustained effectiveness of anticancer therapeutics. One particular modality that has spurred recent interest is the induction of immunogenic cell death (ICD) in which compounds initiate a cytotoxic cascade in cancer cells that trigger a regulated immune response. The promise is that this adaptive immunological cascade leads to the development of acquired immunity against these cancer cells with prolonged anti-tumour protection. Most ICD inducers have been discovered either serendipitously or by library screening. In this presentation, we will discuss the mechanism of action of these complexes, including its ability to trigger calreticulin translocation, an important damage-associated molecular pattern associated with ICD, and consequently, induction of ER stress-dependent phagocytosis in damaged cells.